Business
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced the appointment of Pius Maliakal, M. Pharm., Ph.D., as Vice President of Clinical Operations. Dr. Maliakal will be responsible for the strategy and planning of key clinical operational initiatives, focusing on advancing the Company’s lead clinical trials, ReSPECT-GBM and ReSPECT-LM, and further developing the broader pipeline. Dr. Maliakal is an accomplished R&D professional who brings over 20 years of global and domestic experience to Plus Therapeutics. Prior to joining the Company, he served as Director of Clinical Science at PTC Therapeutics, leading the clinical development, clinical trial operations, strategies, and data interpretations of all oncology assets across the enterprise. Previously, as Director of Clinical Development at Eagle Therapeutics, he led and facilitated the core design and conduct of Phase 1 and 2 clinical trials within breast cancer, lung cancer and other solid tumors. During his prior tenure at Immunomedics, he was instrumental in the Phase 1 through Phase 3 clinical trials of Trodelvy (sacituzumab govitecan) leading to accelerated FDA approval for treatment of triple-negative breast cancer as well as other investigational agents, including unesbulin and emvododstat. Dr. Maliakal earned his M. Pharm. from Nagpur University, India and his Ph.D. from the University of Otago, New Zealand. “Pius has a unique blend of experience in oncologic clinical development and trial operations that will make an immediate positive impact to our team,” said Marc Hedrick, M.D., President and Chief Executive Officer. “As we move our co-lead programs in glioblastoma and leptomeningeal metastases to the next clinical stages, our clinical operational team also needs to expand and advance. We are confident in Pius’ track record of clinical leadership, successful regulatory submissions, early- to late-stage trial preparation and execution with novel investigational therapeutics.” Dr. Maliakal added, “I’m excited to be joining the team at such an important time, and I’m eager to contribute my expertise to support ongoing pipeline development and generate a long...